News

Ahmad Masri, MD, MS, discusses a study he led examining disparities in time to diagnosis of hypertrophic cardiomyopathy using Medicare claims data.

An artificial intelligence can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.

Compared to their usual diet, participants placed in the low sodium diet group—required to keep their sodium intake to 500 mg daily—had their blood pressure reduced by 6 mm Hg.

Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.

David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.

Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.

David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.

Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.

Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.

Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).

David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.

Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.

David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.

Jawaheer and her team used pre-pregnancy data to determine whether there are gene expression biomarkers at the pre-pregnancy baseline that can predict improvement or worsening during pregnancy in patients with rheumatoid arthritis.

FDA approved sotaglifozin (INPEFA®) on May 26, 2023, to treat heart failure. Also, a phase 3 trial shows the clinical benefits of the drug by the 3-month mark.

Results showed decreased mortality rates among patients with severe alcohol-associated hepatitis treated with corticosteroids after the COVID-19 pandemic.

Pooled data from The Liver Meeting showed odevixibat sustains itch and serum bile acid benefits in patients with Alagille syndrome. An investigators shares what he wants to learn next.

Results of ARIES-HM3 demonstrate use of aspirin was associated with an increased rate of major bleeding following HeartMate 3 implantation.

Sumera Ilyas, MBBS, discussed cholangiocarcinoma in primary sclerosing cholangitis and the need for global efforts to improve access to more advanced diagnostic testing.

Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.

We sat down with Jessica Ferrell, PhD, to discuss key takeaways from her session about the developing role of bile acids both for and beyond cholestatic and metabolic diseases.

Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.

Results from this prospective study in Japan found older age, history of hepatocellular carcinoma, and decreased albumin level at SVR were significantly associated with liver-related mortality after SVR.

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.

The study shows rosnilimab's specificity in targeting PD-1 positive T cells, especially the PD-1 high T cells prevalent in inflamed tissues.

We sat down with Ana Lleo, MD, PhD, to discuss primary sclerosing cholangitis biomarkers and the need for future research in this field.

New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.